Highlights
IIA supported (ever)1 patent
About
Proprietary Drugs for Gastrointestinal and Infectious Diseases
RedHill Biopharma is driven to develop extraordinary medicines for people to live extraordinary lives. RedHill applies innovation, focus and a collective mindset of delivering on its promises, to build a company at the forefront of gastrointestinal and infectious diseases management.
Its two FDA-approved drugs are promoted in the U.S. by a dedicated and experienced sales team: Talicia and Aemcolo.
RedHill has also built an exciting, advanced and largely de-risked R&D pipeline of proprietary late-stage clinical development drug candidates addressing major unmet medical needs.
Identity
| Name | RedHill Biopharma |
|---|---|
| Slug | redhill-biopharma |
| Type / kind | startup |
| Crunchbase ID | redhill-biopharma |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6nvN8KDA |
Status
| Status | active |
|---|---|
| Status reason | Public on NASDAQ on Jan, 2012; |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | 21 Haarbaa St., 6473921, Tel Aviv, Israel |
Web & social
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business models
B2B
Tags
inflammatory-diseasescrohn-s-diseasebiopharmaceuticaloral-drugsmedical-productsgastroenterologypharmaceuticalsoncologyhealthcare-providersorphan-drugpatientsinfectious-disease
Funding
| Total raised | $281.8M |
|---|---|
| Current stage | Public |
| Market cap | $5.2M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}